Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Cash & Current Investments (2017 - 2025)

Arcus Biosciences has reported Cash & Current Investments over the past 9 years, most recently at $981.0 million for Q4 2025.

  • Quarterly results put Cash & Current Investments at $981.0 million for Q4 2025, changed 0.31% from a year ago — trailing twelve months through Dec 2025 was $981.0 million (changed 0.31% YoY), and the annual figure for FY2025 was $981.0 million, changed 0.31%.
  • Cash & Current Investments for Q4 2025 was $981.0 million at Arcus Biosciences, up from $831.0 million in the prior quarter.
  • Over the last five years, Cash & Current Investments for RCUS hit a ceiling of $1.2 billion in Q1 2022 and a floor of $499.0 million in Q4 2021.
  • Median Cash & Current Investments over the past 5 years was $961.5 million (2023), compared with a mean of $910.5 million.
  • Peak annual rise in Cash & Current Investments hit 423.82% in 2021, while the deepest fall reached 32.95% in 2021.
  • Arcus Biosciences' Cash & Current Investments stood at $499.0 million in 2021, then surged by 102.2% to $1.0 billion in 2022, then fell by 24.78% to $759.0 million in 2023, then grew by 28.85% to $978.0 million in 2024, then increased by 0.31% to $981.0 million in 2025.
  • The last three reported values for Cash & Current Investments were $981.0 million (Q4 2025), $831.0 million (Q3 2025), and $911.0 million (Q2 2025) per Business Quant data.